Cochrane Review Group

Eyes and Vision

171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.

Reviews

171

Questions

2,112

current versions

No studies

27.8%

Moderate or high

20.2%

No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Eyes and Vision

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	4 studies · 445 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	SMD 1.31	2 studies · 76 participants	Very low
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	1 study · 46 participants	Very low
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane	no estimate extracted	NR	Very low
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	RR 0.73 [0.54, 0.99]	1 study · 239 participants	Very low
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 56 participants	Very low
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	MD 1.8	1 study · 219 participants	Very low
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 217 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	1 study · 262 participants	Very low
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane	no estimate extracted	NR	No studies
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane	OR 1.06	NR	Very low

Reviews 171

Ab interno trabecular bypass surgery with Trabectome for open‐angle glaucoma

Hu, K, Shah, A, et al. · Cochrane Database of Systematic Reviews · 2021

Eyes and Vision

Thinnest evidence

Reviews 171

Ab interno trabecular bypass surgery with Trabectome for open‐angle glaucoma

Intraocular lens optic edge design for the prevention of posterior capsule opacification after cataract surgery

Ab interno supraciliary microstent surgery for open‐angle glaucoma

Pharmacologic interventions for mydriasis in cataract surgery

Photobiomodulation for non‐exudative age‐related macular degeneration

Surgery for idiopathic epiretinal membrane

Surgical interventions for infantile nystagmus syndrome

Transepithelial versus epithelium‐off corneal crosslinking for progressive keratoconus

Corticosteroids for periorbital and orbital cellulitis

Surgical interventions for lamellar macular holes

Oral antibiotics for chronic blepharitis

Virtual reality training for cataract surgery operating performance in ophthalmology trainees

Interventions for preventing ophthalmia neonatorum

Radiotherapy for neovascular age‐related macular degeneration

Interventions to slow progression of myopia in children

Intravitreal steroids for macular edema in diabetes

Acupuncture for glaucoma

Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy

Low vision rehabilitation for better quality of life in visually impaired adults

Spectacle correction versus no spectacles for prevention of strabismus in hyperopic children

Surgical interventions for primary congenital glaucoma

Vitamin A and fish oils for preventing the progression of retinitis pigmentosa

Environmental and behavioural interventions for reducing physical activity limitation and preventing falls in older people with visual impairment

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion

Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration